Media headlines about AstraZeneca (LON:AZN) have been trending somewhat positive on Sunday, according to InfoTrie. The research firm scores the sentiment of media coverage by analyzing more than 6,000 blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AstraZeneca earned a coverage optimism score of 1.52 on their scale. InfoTrie also assigned news coverage about the biopharmaceutical company an news buzz score of 2 out of 10, indicating that recent media coverage is very unlikely to have an effect on the company’s share price in the near term.
Here are some of the headlines that may have effected AstraZeneca’s analysis:
- Project leader: Oxford’s COVID-19 vaccine trial has 50% chance of success – Telegraph (finance.yahoo.com)
- Coronavirus Vaccine: AstraZeneca (AZN) Gets $1 Billion From U.S. – Bloomberg (bloomberg.com)
- A Peek Into AstraZeneca’s P/E Ratio (finance.yahoo.com)
- AstraZeneca: FDA Grants Orphan Drug Designation To Enhertu For Gastric Cancer (nasdaq.com)
- AstraZeneca Receives Over $1B In BARDA Funding For Coronavirus Vaccine (yahoo.com)
LON:AZN opened at GBX 8,996 ($118.34) on Friday. The stock has a market cap of $118.06 billion and a P/E ratio of 77.75. AstraZeneca has a one year low of GBX 5,739 ($75.49) and a one year high of GBX 9,335 ($122.80). The company has a fifty day moving average price of GBX 8,037.56 and a 200 day moving average price of GBX 7,545.94. The company has a debt-to-equity ratio of 171.72, a current ratio of 0.75 and a quick ratio of 0.56.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
See Also: What causes a recession?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.